Hims & Hers Health (NYSE:HIMS) experienced a 40% increase in share price last quarter, possibly fueled by strong financial performance and future growth projections. The company announced earnings on ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

We recently compiled a list of the Wall Street Optimism Spills Over to These 10 Stocks on Friday. In this article, we are ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...